This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MicroConstants Welcomes Pat DeLisio As Director Of East Coast Business Development

SAN DIEGO, April 2, 2013 /PRNewswire/ -- MicroConstants, a regulated bioanalysis and DMPK specialty Contract Research Organization (CRO) in San Diego, California, announces the appointment of Patricia deLisio as their new director of east coast business development. Pat joins MicroConstants' business development team with more than 12 years of experience selling contract research services to companies in the pharmaceutical, biotech, agrochemical, animal health, and specialty chemical industries. As the director of east coast business development, Pat will be responsible for developing new business opportunities in the region and implementing innovative sales and marketing strategies to help further the company's mission of becoming the recognized leader in bioanalytical and pharmacokinetic analysis.

Prior to joining MicroConstants, Pat held business development and program management positions at several bioanalytical and toxicology CROs throughout the United States. She also spent more than three years as an independent GLP quality assurance consultant. Pat began her career as a research chemist, has spent 11 years as a study director/principal investigator, and has extensive experience in HPLC method development and validation for sample analysis supporting regulated toxicology and metabolism studies. Pat received her bachelor's degree in Chemistry from Notre Dame College in South Euclid, Ohio.

"Pat's extensive knowledge of the pharmaceutical development process and her experience establishing and securing new customer opportunities will be a tremendous asset to MicroConstants' business development team as we focus on enhancing our presence in key geographic regions on the east coast," says Gilbert Lam, president and chief scientific officer at MicroConstants. "This new role will also allow us to provide additional resources to our clients throughout the United States."

About MicroConstants, Inc. MicroConstants is a GLP-compliant Contract Research Organization (CRO) focused on performing regulated bioanalysis, drug metabolism and pharmacokinetic analysis to support discovery, preclinical and clinical drug development studies. They specialize in method development, method validation and sample analysis of small molecules, proteins, peptides and metabolites using LC/MS/MS, HPLC/UV, and immunoassay techniques. For more information, please visit

SOURCE MicroConstants

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,787.24 -26.15 -0.15%
S&P 500 2,086.97 -1.90 -0.09%
NASDAQ 5,116.2180 +0.0750 0.00%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs